StreetInsider.com News Articles

Telo Genomics reports blood-based myeloma test outdetects bone marrow method

Tue, 15 Sep 2026 06:32:18 -0400

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) reported clinical research results showing its blood-based TELO-MRD assay detected residual myeloma cells in a higher proportion of matched samples than a standard bone-marrow test in a University of Athens comparison.

Among 42 evaluable matched samples, the company's TeloView-based TELO-MRD assay detected circulating myeloma cells in 39 of 42 samples (92.9%), compared with 23 of 42 samples (54.8%) detected by bone-marrow EuroFlow next-generation flow cytometry. TELO-MRD was positive in 17 of 19 samples that tested negative by the bone-marrow method. The difference was statistically significant (McNemar P=0.000145). The study authors noted the findings require

Telo Genomics reports blood-based myeloma test outdetects bone marrow method

Tue, 15 Sep 2026 06:32:18 -0400

Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse

Tue, 15 Sep 2026 06:30:00 -0400

Proprietary TeloView® blood-based TELO-MRD assay detected residual myeloma cells in a higher proportion of matched samples than bone-marrow next-generation flow cytometry in a University of Athens comparison.

Vancouver, British Columbia--(Newsfile Corp. - September 15, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests based on three-dimensional analysis of telomeres (which are the ends of chromosomes), today reported clinical research results from its TELO-MRD program in multiple myeloma.

TELO-MRD is a new liquid-biopsy approach to Minimal Residual Disease (MRD) testing. It combines enumeration

Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse

Tue, 15 Sep 2026 06:30:00 -0400

TELO-MRD is a new liquid-biopsy approach to Minimal Residual Disease (MRD) testing. It combines enumeration

Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse

Tue, 15 Sep 2026 06:30:00 -0400

TELO-MRD is a new liquid-biopsy approach to Minimal Residual Disease (MRD) testing. It combines enumeration

Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse

Tue, 15 Sep 2026 06:30:00 -0400

TELO-MRD is a new liquid-biopsy approach to Minimal Residual Disease (MRD) testing. It combines enumeration

Telo Genomics Grants Stock Options

Tue, 04 Aug 2026 06:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, announces the grant of stock options (the "Options") pursuant to its stock option plan to purchase up to an aggregate of 3,300,000 common shares of the Company, subject to TSX Venture Exchange approval, of which 2,500,000 Options were granted to directors and officers, 600,000 Options to employees, and 200,000 Options to consultants of the Company. The Options are exercisable at

Telo Genomics Grants Stock Options

Tue, 04 Aug 2026 06:30:00 -0400

Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment

Thu, 16 Jul 2026 07:00:00 -0400

Clinical Study on Track to Meet Primary Endpoints with Interim Data Demonstrating Blood-Based Assay Capable of Predicting Relapse Risk Through Analysis of Genomic Instability and Telomere Architecture

Vancouver, British Columbia--(Newsfile Corp. - July 16, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the 3D analysis of telomeres (which are the ends of chromosomes), announced positive interim results from an ongoing retrospective clinical study conducted in collaboration with National and Kapodistrian University of Athens. The clinical trial, which is expected to conclude

Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment

Thu, 16 Jul 2026 07:00:00 -0400

Telo Genomics files patent for liquid biopsy MRD use in myeloma

Thu, 09 Jul 2026 07:02:18 -0400

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) has filed a U.S. provisional patent application to protect a new TeloView biomarker algorithm designed for use with liquid biopsy samples in the management of multiple myeloma patients, including those with minimal residual disease (MRD).

The application seeks to cover an algorithm that can predict relapse risk in multiple myeloma patients, as well as a workflow to isolate circulating cancer cells from peripheral blood samples in the MRD setting.

"This filing reflects our continued focus on building intellectual property around high-value applications of the TeloView platform," said John Farlinger, Telo's CEO.

Currently available MRD technologies primarily

Telo Genomics files patent for liquid biopsy MRD use in myeloma

Thu, 09 Jul 2026 07:02:18 -0400

"This filing reflects our continued focus on building intellectual property around high-value applications of the TeloView platform," said John Farlinger, Telo's CEO.

Currently available MRD technologies primarily

Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma

Thu, 09 Jul 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 9, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced telomere analytics, today announced that it has filed a U.S. provisional patent application seeking to protect a new TeloView® biomarker algorithm for use with liquid biopsy samples, even those with minimal residual disease ("MRD") in the management of patients with multiple myeloma ("MM").

"This filing reflects our continued focus on building intellectual property around high-value applications of the TeloView® platform," said John Farlinger, Telo's CEO. "As MRD becomes increasingly important in multiple myeloma

Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma

Thu, 09 Jul 2026 07:00:00 -0400

Telo Genomics Announces Termination of Investor Relations Agreement

Fri, 26 Jun 2026 20:58:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 26, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, announces that the investor relations consulting agreement with Sheridan Adams, LLC ("Sheridan"), as announced on March 31, 2026, has been terminated effective June 12, 2026. It was initially understood between the parties that this was a transitory role for Sheridan and was not intended to be long term. The Company wishes Sheridan well with its future endeavours.

About Telo Genomics

Telo

Telo Genomics Announces Termination of Investor Relations Agreement

Fri, 26 Jun 2026 20:58:00 -0400

About Telo Genomics

Telo

Form D Telo Genomics Corp.

Fri, 24 Apr 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260424/26366764.html

Form D Telo Genomics Corp.

Fri, 24 Apr 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260424/26366764.html

Form D Telo Genomics Corp.

Fri, 24 Apr 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260424/26366764.html

Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma

Tue, 14 Apr 2026 07:00:00 -0400

Clinical Trial Seeks to Validate Novel Blood-Based Assay that Predicts Relapse Risk by Analyzing the Biologic Behavior of Remaining Cancer Cells, Addressing Critical Gaps in Current Minimal Residual Disease (MRD) Testing

Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the 3D analysis of telomeres (which are the ends of chromosomes) today announced the launch of a new retrospective clinical study in collaboration with leading hematologists at the National and Kapodistrian University of Athens, Dr.

Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma

Tue, 14 Apr 2026 07:00:00 -0400

Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman

Tue, 31 Mar 2026 07:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - March 31, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, has appointed John Farlinger, currently chair of the Company's audit committee, as chief executive officer and chairman. In connection with Mr. Farlinger's appointment, the Company and Mr. Farlinger have entered into a management consulting agreement. Mr. Farlinger is a seasoned public markets, venture and private equity-backed executive and entrepreneur, bringing more than 30 years of experience in operations, technology and

Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman

Tue, 31 Mar 2026 07:00:00 -0400

Telo Genomics Closes Second and Final Tranche of Convertible Debentures Financing

Mon, 09 Mar 2026 07:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement offering (the "Offering") of non-transferable secured convertible debentures ("Debentures") (see news releases dated January 19, 2026, February 18, 2026, and February 27, 2026) by issuing Debentures for gross proceeds of $545,000 (the "Second Tranche"), for aggregate gross proceeds from the

Telo Genomics Closes Second and Final Tranche of Convertible Debentures Financing

Mon, 09 Mar 2026 07:00:00 -0400